Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kymera Therapeutics (KYMR) Liabilities and Shareholders Equity (2019 - 2025)

Kymera Therapeutics (KYMR) has disclosed Liabilities and Shareholders Equity for 7 consecutive years, with $1.7 billion as the latest value for Q4 2025.

  • On a quarterly basis, Liabilities and Shareholders Equity rose 78.2% to $1.7 billion in Q4 2025 year-over-year; TTM through Dec 2025 was $4.9 billion, a 32.02% increase, with the full-year FY2025 number at $1.7 billion, up 78.2% from a year prior.
  • Liabilities and Shareholders Equity was $1.7 billion for Q4 2025 at Kymera Therapeutics, up from $1.1 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $1.7 billion in Q4 2025 to a low of $434.4 million in Q2 2021.
  • A 5-year average of $770.0 million and a median of $626.2 million in 2022 define the central range for Liabilities and Shareholders Equity.
  • Peak YoY movement for Liabilities and Shareholders Equity: fell 13.48% in 2023, then surged 87.34% in 2024.
  • Kymera Therapeutics' Liabilities and Shareholders Equity stood at $605.9 million in 2021, then dropped by 0.46% to $603.1 million in 2022, then fell by 4.54% to $575.8 million in 2023, then skyrocketed by 69.87% to $978.0 million in 2024, then skyrocketed by 78.2% to $1.7 billion in 2025.
  • Per Business Quant, the three most recent readings for KYMR's Liabilities and Shareholders Equity are $1.7 billion (Q4 2025), $1.1 billion (Q3 2025), and $1.1 billion (Q2 2025).